| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | 7% YoY overall; API revenue grew 6% YoY on volumes. |
|---|---|
| Margins | API gross margins stable at 60%+; consolidated margins dragged by capex. |
| Order book | Multi-year take-or-pay contracts secured for insulin and alternative proteins. |
| Demand visibility | Strong traction in synthetic biology; order book 'over the roof'. |
| Management confidence | Extremely bullish on biotech shifts; confident in H2 FY27 recovery. |
Growth
Core API business grew 6% YoY on volumes; new CDMO/Injectables segments contribute ₹34 Cr in combined costs without revenue.
Outlook
Management guides 20% revenue and 25% EBITDA growth for FY27, backed by Q3/Q4 milestone cashflows.
Risks
Substantial ₹1,000 Cr+ capex remains unmonetized; new business segments face high depreciation and operating expense drag in early FY27.
Earnings Call Transcript filed with NSE, NSE: SYMBIOTEC. Summary written with AI assistance from the document.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,003.35
- Market cap
- ₹6,447 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Results Update
Symbiotec Pharmalab released its Q1FY27 investor update. The company reported consolidated revenue of Rs. 218.2 Crore and PAT of Rs. 14.1 Crore for the period.
Symbiotec Pharmalab Investor Presentation: Key Takeaways
Symbiotec Pharmalab Q1FY27 results show steady 7% revenue growth in core API business, offset by high opex/depreciation from significant new capex in Injectables and CDMO services.
Symbiotec Pharmalab Q1 FY27 Results: Net Profit ₹14.1 Cr, Down 52.8% YoY
Symbiotec Pharmalab Ltd reported revenue from operations of ₹218.2 Cr (+7.4% YoY) and net profit of ₹14.1 Cr (-52.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹14.1 Cr · -52.8% YoY
Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab Ltd scheduled a board meeting for September 21, 2026, to consider financial results for the quarter ended June 30, 2026.
Symbiotec Pharmalab Share Pledge
Symbiotec Pharmalab promoters pledged 34.93 lakh shares (~5.44%) to debenture trustee Beacon Trusteeship. This Securitisation encumbrance secures the company's debenture issue.
Symbiotec Pharmalab Capital Structure Change
Mirae Asset Mutual Fund acquired 34,97,420 shares of Symbiotec Pharmalab Ltd. This open market purchase increased their stake from 0.78% to 6.22%.